Iptacopan

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Glomerulonephritis, IGA

Conditions

Glomerulonephritis, IGA, Immunoglobulin A Nephropathy

Trial Timeline

Feb 21, 2025 → Nov 27, 2027

NCT ID

NCT06797518

About Iptacopan

Iptacopan is a phase 2 stage product being developed by Novartis for Glomerulonephritis, IGA. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06797518. Target conditions include Glomerulonephritis, IGA, Immunoglobulin A Nephropathy.

What happened to similar drugs?

0 of 1 similar drugs in Glomerulonephritis, IGA were approved

Approved (0) Terminated (0) Active (1)

🔄RamiprilSanofiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05222412	Pre-clinical	Active	—	—	C3 Glomerulopathy (C3G)
NCT06994845	Phase 3	Recruiting	Nov 27, 2025	Jun 30, 2030	Primary Immunoglobulin A Nephropathy (IgAN)
NCT06903234	Pre-clinical	Active	Mar 31, 2025	Oct 1, 2029	Hemoglobinuria, Paroxysmal
NCT06797518	Phase 2	Recruiting	Feb 21, 2025	Nov 27, 2027	Glomerulonephritis, IGA
NCT06517758	Phase 3	Recruiting	Jul 31, 2024	May 27, 2032	Generalized Myasthenia Gravis
NCT05935215	Phase 3	Recruiting	Feb 28, 2024	Jul 19, 2029	Atypical Hemolytic Uremic Syndrome
NCT05630001	Phase 3	Completed	Apr 24, 2023	Oct 17, 2024	Paroxysmal Nocturnal Hemoglobinuria
NCT04889430	Phase 3	Active	Jan 17, 2022	Aug 13, 2026	Atypical Hemolytic Uremic Syndrome
NCT05086744	Phase 2	Terminated	Dec 21, 2021	May 17, 2024	Immune Thrombocytopenia (ITP)
NCT04747613	Phase 3	Active	Jul 27, 2021	Oct 19, 2027	Paroxysmal Nocturnal Hemoglobinuria
NCT03439839	Phase 2	Completed	Apr 9, 2018	Feb 28, 2022	Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis

Competing Products

8 competing products in Glomerulonephritis, IGA

See all competitors

Product	Company	Stage	Hype Score
olmesartan medoxomil	Daiichi Sankyo	Phase 2	35
infusion of ADR-001 (Mesenchymal stem cell)	Rohto Pharmaceutical	Phase 1	29
LNP023	Novartis	Phase 2	35
mycophenolate mofetil orally 1000 mg twice a day (BID) + prednisone 0,5 mg/kg orally on alternate days + intravenous (i.v.) methylprednisolone 1000 mg, total 9	Roche	Phase 2/3	38
ACE inhibitor + statin + Sirolimus (study drug)+ACE inhibitor + statin	Pfizer	Phase 2	35
Ramipril	Sanofi	Phase 3	40
MOR202	Biogen	Phase 1/2	29
MOR202	Biogen	Phase 2	32